www.scottishmedicines.org.uk

Healthcare Improvement Scotland | SMC Advice on new medicines

Product update
SMC2123

buprenorphine/naloxone 1.4mg/0.36mg, 2.9mg/0.71mg, 5.7mg/1.4mg, 8.6mg/2.1mg, 11.4mg/2.9mg sublingual tablets (Zubsolv®)

Accord Healthcare

9 November 2018 (*Issued 07 October 2022*)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

buprenorphine/naloxone (Zubsolv®) is accepted for restricted use within NHSScotland.

Indication under review: substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

SMC restriction: for use in patients for whom methadone is not suitable.

Buprenorphine/naloxone (Zubsolv®) is available at a slightly lower cost when compared to another buprenorphine/naloxone combination product.

Prescribers should be aware that buprenorphine preparations are not interchangeable.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 09 October 2018.

Chairman
Scottish Medicines Consortium